ARV-471也是目前首款进入临床3期的PROTAC，辉瑞和Arvinas于去年12月16日Clinicaltrials.gov网站上注册了ARV-471的首个三期临床VERITAC-2试验（NCT05654623），用于治疗晚期复发性乳腺癌。该三期临床计划入组561例晚期复发性乳腺癌患者，与氟维司群头对头对照，预计2024年初步完成。近期，Hamilton等人进一步更新了在额外1...
ARV-471也是目前首款进入临床3期的PROTAC,辉瑞和Arvinas于去年12月16日Clinicaltrials.gov网站上注册了ARV-471的首个三期临床VERITAC-2试验(NCT05654623),用于治疗晚期复发性乳腺癌。该三期临床计划入组561例晚期复发性乳腺癌患者,与氟维司群头对头对照,预计2024年初步完成。 近期,Hamilton等人进一步更新了在额外13个...
ARV-471也是目前首款进入临床3期的PROTAC,辉瑞和Arvinas于去年12月16日http://Clinicaltrials.gov网站上注册了ARV-471的首个三期临床VERITAC-2试验(NCT05654623),用于治疗晚期复发性乳腺癌。该三期临床计划入组561例晚期复发性乳腺癌患者,与氟维司群头对头对照,预计2024年初步完成。 近期,Hamilton等人进一步更新了在...
ARV-471也是目前首款进入临床3期的PROTAC,辉瑞和Arvinas于去年12月16日Clinicaltrials.gov网站上注册了ARV-471的首个三期临床VERITAC-2试验(NCT05654623),用于治疗晚期复发性乳腺癌。该三期临床计划入组561例晚期复发性乳腺癌患者,与氟维司群头对头对照,预计2024年初步完成。 近期,Hamilton等人进一步更新了在额外13个...
Although several PROTACs have now entered clinical trials, potential off-tissue side effects have resulted from nonspecific accumulation at non-cancerous sites after systemic administration, and this remains a major challenge. To this end, in the past 3 years, activatable PROTACs whose activity can ...
drugging the undruggable proteins in cancer: a systems biology approach. curr. opin. chem. biol. 66, 102079. adjei, a.a. (2006) what is the right dose? the elusive optimal biologic dose in phase i clinical trials. j. clin. oncol. 24, 4054–405...
ARV-471是Arvinas进展最快的产品,也是目前首款进入临床3期的PROTAC,Arvinas于去年12月16日Clinicaltrials.gov网站上注册了ARV-471的首个三期临床VERITAC-2试验(NCT05654623),招募560名患者,用于治疗晚期复发性乳腺癌(图3)。 图3. ARV-471的首个临床3期试验设计[1] ...
discovered two orally bioavailable PROTACs which have been successfully tested in phase II clinical trials. One if ER PROTAC ARV-471 for the treatment of breast cancer and AR PROTAC ARV-110 for the treatment of prostate cance...
The discussion extends to the challenges, nanotechnology applications, and ongoing clinical trials, showcasing promising results and clinical progress. The review concludes with insights into patents, future directions, and the potential impact of PROTACs in addressing dysregulated protein expression across ...
which play important roles in cancer biology. Inhibitors of c-Met kinase have been developed in the past near 20 years, but they have been disappointing in clinical trials. This suggested that a kinase-independent function might drive oncogenesis and degradation and might be a potential advantage...